This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Click here for BeneFIX® (nonacog alfa) Prescribing Information.  Adverse event reporting information can be found at the bottom of the page.

BeneFIX can be given as on-demand treatment or as prophylaxis

On-demand treatment1

The calculation of the required dose of BeneFIX can be based on the finding that one unit of factor IX activity per kg body weight is expected to increase the circulating level of factor IX, an average of 0.8 IU/dl (range from 0.4 to 1.4 IU/dl) in patients ≥12 years.

The required dose is determined using the following formula: number of factor IX IU required = body weight (kg) x desired factor IX increase (% or IU/dl) x reciprocal of observed recovery.

The amount to be administered and the frequency of administration should always be oriented to the clinical effectiveness in the individual case.
In the case of the following haemorrhagic events, the factor IX activity should not fall below the given plasma activity levels (in percentage of normal or in IU/dl) in the corresponding period. The following table can be used to guide dosing in bleeding episodes and surgery:

Degree of haemorrhage / Type of surgical procedure

Factor IX level required (%) or (IU/dl)

Frequency of doses (hours) / Duration of therapy (days)


Early haemarthrosis, muscle bleeding or oral bleeding


Repeat every 24 hours. At least 1 day, until the bleeding episode as indicated by pain is resolved or healing is achieved.

More extensive haemarthrosis, muscle bleeding or haematoma


Repeat infusion every 24 hours for 3–4 days or more until pain and acute disability are resolved.

Life-threatening haemorrhage


Repeat infusion every 8–24 hours until threat is resolved.


Minor, including tooth extraction


Every 24 hours, at least 1 day, until healing is achieved.


80–100 (pre- and post-operative)  

Repeat infusion every 8–24 hours until adequate wound healing, then therapy for at least another
7 days to maintain a factor IX activity of 30% to 60% (IU/dL)

Adapted from BeneFIX (nonacog alfa) Summary of Product Characteristics.1


BeneFIX may be administered for long-term prophylaxis against bleeding in patients with haemophilia B. In a clinical study for routine secondary prophylaxis the average dose for PTPs was 40 IU/kg (range 13–78 IU/kg) at intervals of 3–4 days.1

In some cases, especially in younger patients, shorter dosage intervals or higher doses may be necessary.

Explore more

Find out about flexible dosing & dosing optimisation with BeneFIX

Click here

Find out about administration & reconstitution of BeneFIX

Click here

  1. BeneFIX (nonacog alfa) Summary of Product Characteristics:
PP-BEN-GBR-0392. March 2021

Find out about BeneFIX efficacy 

Click here

Educational materials for children with Haemophilia

Find out more

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020